In Indeterminate Thyroid Nodules
NEW Validation Study Demonstrates
Highest PPV and High NPV1*
Multicenter, retrospective, blinded validation study of 309 subjects with indeterminate thyroid nodules (Bethesda III, IV, or V) and corresponding surgical histology. Gold-standard unanimous consensus histopathology diagnosis (n=197) among three pathologists was used and all molecular testing was performed using archived cytology smears. Results were reported as negative, moderate, or positive based on the combined test results from both ThyGeNEXT® (mutation panel) and ThyraMIR® (microRNA risk classifier). Additional histopathologic subtype prevalence adjustments were used to determine the impact of Spectrum Effect biases on test performance. The analysis showed that test performance was optimal in a histopathologic subtype population encountered in clinical practice.
Compared to other marketed tests,3,4 results demonstrated that microRNA and mutation panel combination testing had the highest PPV (positive predictive value) at 75% and similar NPV (negative predictive value) at 97% (n=178, prevalence-adjusted). microRNA classification further risk-stratified patients with weak driver mutations, including RAS, resulting in four out of five nodules being accurately ruled-in or ruled-out for disease. Prevalence-unadjusted PPV and NPV were 74% and 95%, respectively.
Interpace Diagnostics is the only company that offers:
Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that a peer-reviewed
In-Network Access for More Than 3 Million Members Parsippany, NJ, April 27, 2020 (GLOBE NEWSWIRE) — Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace Diagnostics, has entered into
Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) — Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue
1. Lupo MA, et al. Diagn Cytopathol. 2020;1–11. https://doi.org/10.1002/dc.24564. 2. Banizs AB, Silverman JF. Diagn Cytopathol. 2019;47(4):268-274. 3. Steward DL, et al. JAMA Oncol. 2019;5(2):204-212. 4. Patel KN, et al. JAMA Surg. 2018;153(9):817-824.
Interpace Diagnostics is a registered trademark and business unit of Interpace Biosciences, Inc.™
©2020 Interpace Biosciences, Inc.™ All rights reserved.
